Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tozasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB known ✓ | Q96GD4 | 12/20 | 0.78 |
| ▸ | AURKA known ✓ | O14965 | 11/20 | 0.78 |
| ▸ | AURKC known ✓ | Q9UQB9 | 2/20 | 0.78 |
| ▸ | PLK4 | O00444 | 3/20 | 0.78 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.78 |
| ▸ | ABL1 | P00519 | 2/20 | 0.78 |
| ▸ | BCR | P11274 | 2/20 | 0.78 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.78 |
| ▸ | STK25 | O00506 | 1/20 | 0.78 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.78 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.78 |
| ▸ | GAK | O14976 | 1/20 | 0.78 |
| ▸ | MUSK | O15146 | 1/20 | 0.78 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.78 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.78 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.78 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.78 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.78 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.78 |
| ▸ | JAK2 | O60674 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12338916 | 0.93 | AURKB (0.77) | AURKBAURKAPLK4RIPK1AURKC | |
| SCHEMBL12338737 | 0.93 | AURKA (0.67) | AURKBAURKAPLK4RIPK1AURKC | |
| SCHEMBL12338745 | 0.92 | AURKA (0.67) | AURKBAURKAPLK4RIPK1AURKC | |
| SCHEMBL12694190 | 0.92 | AURKA (0.66) | AURKBAURKAPLK4RIPK1AURKC | |
| SCHEMBL12102753 | 0.91 | AURKA (0.65) | AURKBAURKAPLK4RIPK1AURKC | |
| SCHEMBL12338932 | 0.91 | AURKB (0.65) | AURKBAURKAPLK4RIPK1AURKC | |
| SCHEMBL13799832 | 0.91 | AURKB (0.65) | AURKBAURKAPLK4RIPK1AURKC | |
| SCHEMBL14386533 | 0.90 | AURKA (0.64) | AURKBAURKAPLK4RIPK1AURKC | |
| SCHEMBL12338758 | 0.90 | AURKA (0.77) | AURKBAURKAPLK4RIPK1AURKC | |
| SCHEMBL12338763 | 0.90 | AURKB (0.72) | AURKBAURKAPLK4RIPK1AURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20240317733-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-09-26 | — | — | US | disclosed |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-20220365074-A1 | METHODS AND SYSTEMS FOR DETERMINING VIRUSES SUCH AS CORONAVIRUSES USING pH | ANALIZA, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-11357776-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-17 | — | — | US | disclosed |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10928405-B2 | Devices and methods for determining and/or isolating cells such as circulating cancer or fetal cells | ANALIZA, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008115890-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | WO | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1904498-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008016192-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
| WO-2007087246-A2 | JAK2 TYROSINE KINASE INHIBITION | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007014250-A2 | ABL KINASE INHIBITION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007004749-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | IGF1R, INSR, ERBB3 | AURKB 1423/4885AURKA 1276/4885AURKC 577/4885 |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | AURKB 3299/4885AURKA 3174/4885AURKC 4251/4885 |
| US-20240317733-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | AURKB 3252/4885AURKA 3152/4885AURKC 4256/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | AURKB 162/4885AURKA 183/4885AURKC 93/4885 |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | AURKB 3299/4885AURKA 3174/4885AURKC 4251/4885 |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | HDAC1, HDAC3, HDAC8 | AURKB 15/4885AURKA 23/4885AURKC 7/4885 |
| US-11357776-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | HDAC1, HDAC3, HDAC8 | AURKB 15/4885AURKA 23/4885AURKC 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.